Respiratory patient experience of measures to reduce risk of COVID-19: findings from a descriptive cross-sectional UK wide survey.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
09 09 2020
Historique:
entrez: 11 9 2020
pubmed: 12 9 2020
medline: 23 9 2020
Statut: epublish

Résumé

To assess the experience of people with long-term respiratory conditions regarding the impact of measures to reduce risk of COVID-19. Analysis of data (n=9515) from the Asthma UK and British Lung Foundation partnership COVID-19 survey collected online between 1 and 8 April 2020. Community. 9515 people with self-reported long-term respiratory conditions. 81% female, age ranges from ≤17 years to 80 years and above, from all nations of the UK. Long-term respiratory conditions reported included asthma (83%), chronic obstructive pulmonary disease (10%), bronchiectasis (4%), interstitial lung disease (2%) and 'other' (<1%) (eg, lung cancer and pulmonary endometriosis). Study responses related to impacts on key elements of healthcare, as well as practical, psychological and social consequences related to the COVID-19 pandemic and social distancing measures. 45% reported disruptions to care, including cancellations of appointments, investigations, pulmonary rehabilitation, treatment and monitoring. Other practical impacts such as difficulty accessing healthcare services for other issues and getting basic necessities such as food were also common. 36% did not use online prescriptions, and 54% had not accessed online inhaler technique videos. Psychosocial impacts including anxiety, loneliness and concerns about personal health and family were prevalent. 81% reported engaging in physical activity. Among the 11% who were smokers, 48% reported they were planning to quit smoking because of COVID-19. COVID-19 and related social distancing measures are having profound impacts on people with chronic respiratory conditions. Urgent adaptation and signposting of services is required to mitigate the negative health consequences of the COVID-19 response for this group.

Identifiants

pubmed: 32912958
pii: bmjopen-2020-040951
doi: 10.1136/bmjopen-2020-040951
pmc: PMC7482474
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e040951

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):5797-801
pubmed: 23530191
BMJ Open Respir Res. 2019 Oct 3;6(1):e000478
pubmed: 31673369
Thorax. 2019 Aug;74(8):814-817
pubmed: 30962273
COPD. 2013 Feb;10(1):40-54
pubmed: 23272667
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
BMJ. 2020 Apr 27;369:m1557
pubmed: 32341002
Thorax. 2017 Jun;72(6):530-537
pubmed: 28077613
BMJ. 2019 Jul 29;366:l4486
pubmed: 31358491
Brain Behav Immun. 2020 Jul;87:40-48
pubmed: 32298802
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
Thorax. 2020 Jul;75(7):597-599
pubmed: 32317268
Gen Hosp Psychiatry. 2011 May-Jun;33(3):217-23
pubmed: 21601717
Respirology. 2016 Apr;21(3):497-503
pubmed: 26647766
Int J Environ Res Public Health. 2020 Jun 08;17(11):
pubmed: 32521776
Res Aging. 2004;26(6):655-672
pubmed: 18504506
BMJ. 2020 Mar 23;368:m1170
pubmed: 32205309
Brain Behav Immun. 2020 Jul;87:84-92
pubmed: 32335200
Thorax. 2014 Nov;69(11):973-5
pubmed: 24985493
Int J Environ Res Public Health. 2020 Mar 06;17(5):
pubmed: 32155789
Br J Psychiatry. 2020 Oct;217(4):543-546
pubmed: 32654678
J Public Health (Oxf). 2011 Mar;33(1):108-16
pubmed: 20522452

Auteurs

Keir Philip (K)

National Heart and Lung Institute, Imperial College London, London, UK k.philip@imperial.ac.uk.

Andrew Cumella (A)

Asthma UK and British Lung Foundation Partnership, London, UK.

Joe Farrington-Douglas (J)

Asthma UK and British Lung Foundation Partnership, London, UK.

Michael Laffan (M)

Asthma UK and British Lung Foundation Partnership, London, UK.

Nicholas Hopkinson (N)

National Heart and Lung Institute, Imperial College London, London, UK.
Asthma UK and British Lung Foundation Partnership, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH